Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organization (CRO) headquartered in Wilmington, Massachusetts. Founded in 1947, the company's core business is to provide essential products and services that accelerate the discovery, development, and safe manufacture of new therapies for pharmaceutical and biotechnology companies, government agencies, and academic institutions globally. Its mission is to partner with clients to bring life-saving treatments to patients.

The company operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment provides laboratory animals, including genetically engineered models, and related diagnostic and insourcing services. The DSA segment offers preclinical and clinical laboratory services, such as safety assessment, toxicology studies, and bioanalysis. The Manufacturing Solutions segment focuses on microbial solutions, biologics testing, avian vaccine services, and contract manufacturing for cell and gene therapies.

In a notable leadership transition, James C. Foster is set to retire as Chairman, President, and CEO on May 5, 2026, with Birgit Girshick, currently COO, appointed as his successor. Dr. Martin Mackay will assume the role of Chair of the Board. Recent developments include the launch of rat In Vitro Fertility (IVF) services in April 2026 and new executive appointments for Chief Financial Officer and Chief Legal Officer in February 2026. Charles River Laboratories is recognized as one of the largest CROs globally, playing a significant role in the drug discovery and development services sector.

Latest updates

Charles River Expands IVF Services to Rat Models, Challenging Breeding Bottlenecks

Event summary

  • Charles River Laboratories has launched an enhanced In Vitro Fertility (IVF) service bundle specifically for rat models.
  • The service aims to accelerate research programs in therapeutic areas like oncology, neurology, cardiology, and metabolic.
  • Charles River’s Genetically Engineered Model Services (GEMS) will manage customized breeding plans and logistics.
  • The IVF service, previously utilized in mouse models, is being offered to rat models following protocol modifications.
  • The service is available for quote requests starting in Q2 2026.

The big picture

Charles River’s move to offer rat IVF services represents a strategic expansion within the contract research organization (CRO) market, addressing a persistent challenge in preclinical drug development: breeding bottlenecks. This service directly tackles the inefficiencies of traditional rat breeding, potentially reducing timelines and costs for pharmaceutical and biotech clients. The adoption of IVF, previously established in mouse models, signals a broader trend towards advanced reproductive technologies in preclinical research.

What we're watching

Market Adoption
The success of this offering hinges on investigator adoption; rat models represent a significant portion of preclinical research, and the service’s value proposition must demonstrably outweigh existing breeding methods.
Competitive Response
Other CROs offering animal model services will likely evaluate Charles River’s IVF offering and may develop competing solutions, potentially impacting pricing and market share.
Technical Scalability
The ability to consistently deliver high-quality IVF rat models at scale will be crucial; early adoption rates and client feedback will reveal potential bottlenecks in the process.
CID: 3774